Phase 1 Clinical Trial Begins for Malaria Vaccine Candidate Based on iBio's Proprietary Technology
February 10, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Feb 10, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leader in plant-based biotechnology for developing and manufacturing biological products, reported the initiation of a...
iBio Adds Biotherapeutic Product for Treatment of Fibrosis to Its Proprietary Product Pipeline
January 30, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 30, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biopharmaceutical products, has added a...
iBio Receives Allowance of Patent for HPV-Related Cancer Vaccine in China
January 21, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 21, 2014) - iBio, Inc. (NYSE MKT: IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, has received a notice...
iBio and Caliber Designate New Fusion Protein as Target Product Under License and Collaboration Agreement
January 15, 2014 08:31 ET
|
iBio, Inc.
NEWARK, DE--(Marketwired - Jan 15, 2014) - iBio, Inc. (NYSE MKT: IBIO) announced today that the company and Caliber Biotherapeutics have designated a proprietary fusion protein for cancer...